^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Comparative real-world analysis of pembrolizumab plus chemo vs platinum-doublet alone in metastatic nonsquamous NSCLC with PD-L1 low

Published date:
03/23/2022
Excerpt:
In the context of chemo-IO combo, our study aims to compare platinum-pemetrexed-pembrolizumab (PPP) combo to platinum-doublet alone in pts with low PD-L1 (<50%)…KRAS G12C was associated with better PFS (HR 0.33, 95%CI 0.11-1.04).
Secondary therapy:
pemetrexed